Pipeline

TechnoPhage currently holds a well-balanced and diversified product portfolio addressing key therapeutic and non-therapeutic areas while simultaneously being agile in meeting the challenges of the rapidly evolving pharmaceutical industry.

Therapeutic products

Infection

DiscoveryPreclinicalIND/CTAPhase IPhase IIPhase III

  • Chronic ulcers (TP-102) 84% 84%
  • Respiratory infection (TP-122) 49.8% 49.8%
  • Urinary tract infection (TP-164) 29% 29%

Neuroscience

DiscoveryPreclinicalIND/CTAPhase IPhase IIPhase III

  • Parkinson’s disease (TZ-113) 41.5% 41.5%
  • Spinal cord injury (TZ-161) 41.5% 41.5%
  • Undisclosed indication (TA-191) 16% 16%

Ophthalmology

DiscoveryPreclinicalIND/CTAPhase IPhase IIPhase III

  • Undisclosed indication (TA-182) 16% 16%

Non-therapeutic products

Biomarkers

DiscoveryPreclinicalClinical

  • Biomarker (TA-111C) 65% 65%
  • Biomarker (TA-211) 32% 32%

Others

DiscoveryPreclinical

  • Novel food (C1) 87.5% 87.5%

Therapeutic products

Non-therapeutic products